Overexpression of MicroRNA-367 Inhibits Angiogenesis in Ovarian Cancer by Downregulating the Expression of LPA1

Overview

Journal Cancer Cell Int

Publisher Biomed Central

Date 2020 Oct 7

PMID 33024414

Citations 2

Authors

Qingling Zheng

Xin Dai

Wei Fang

Yan Zheng

Jin Zhang

Yanxiang Liu

DongHua Gu

Affiliations

Soon will be listed here.

Abstract

Background: Compelling evidences reported the role of microRNAs (miRNAs) in ovarian cancer. However, little was known regarding the molecular mechanism of miR-367 in ovarian cancer. This study intended to investigate the role and regulatory mechanism of miR-367 in ovarian cancer involving lysophosphatidic acid receptor-1 (LPA1).

Methods: Potentially regulatory miRNAs in ovarian cancer were obtained from bioinformatics analysis. RT-qPCR was used to detect miR-367 expression in both ovarian cancer tissues and relevant adjacent normal tissues. Relationship between miR-367 and LPA1 was predicted by miRNA database and further verified using dual luciferase reporter gene assay and RIP. EdU and Transwell assay were used to measure the proliferation and invasion ability of cells. Moreover, tube formation and chick chorioallantois membrane (CAM) assay were performed to determine angiogenesis of human umbilical vein endothelial cells (HUVECs). Finally, the roles of LPA1 in tumor growth was also studied using nude mice xenograft assay.

Results: High expression of LPA1 and low expression of miR-367 were observed in ovarian cancer tissues and cells. Overexpressed miR-367 downregulated LPA1 expression to inhibit proliferation, invasion, and angiogenesis of cancer cells. Low expression of LPA1 suppressed tumor formation and repressed angiogenesis in ovarian in vivo.

Conclusion: All in all, overexpression of miR-367 downregulated LPA1 expression to inhibit ovarian cancer progression, which provided a target for the cancer treatment.

Citing Articles

Competing endogenous RNA networks in ovarian cancer: from bench to bedside.

Derogar R, Nejadi Orang F, Shadbad M EXCLI J. 2025; 24:86-112.

PMID: 39967908 PMC: 11830916. DOI: 10.17179/excli2024-7827.

The Emerging Role of LPA as an Oncometabolite.

Karalis T, Poulogiannis G Cells. 2024; 13(7.

PMID: 38607068 PMC: 11011573. DOI: 10.3390/cells13070629.

MicroRNA-367-3p directly targets RAB23 and inhibits proliferation, migration and invasion of bladder cancer cells and increases cisplatin sensitivity.

Wei X, Jiang Y, Yang G, Chang T, Sun G, Chen S J Cancer Res Clin Oncol. 2023; 149(20):17807-17821.

PMID: 37935937 PMC: 10725407. DOI: 10.1007/s00432-023-05484-6.

References

Sattikar A, Dowling M, Rosethorne E . Endogenous lysophosphatidic acid (LPA ) receptor agonists demonstrate ligand bias between calcium and ERK signalling pathways in human lung fibroblasts. Br J Pharmacol. 2016; 174(3):227-237. PMC: 5241385. DOI: 10.1111/bph.13671. View

Nakayama M, Nakayama A, van Lessen M, Yamamoto H, Hoffmann S, Drexler H . Spatial regulation of VEGF receptor endocytosis in angiogenesis. Nat Cell Biol. 2013; 15(3):249-60. PMC: 3901019. DOI: 10.1038/ncb2679. View

Chen N, Chon H, Xiong Y, Marchion D, Judson P, Hakam A . Human cancer cell line microRNAs associated with in vitro sensitivity to paclitaxel. Oncol Rep. 2013; 31(1):376-83. PMC: 3981115. DOI: 10.3892/or.2013.2847. View

Yu X, Zhang Y, Chen H . LPA receptor 1 mediates LPA-induced ovarian cancer metastasis: an in vitro and in vivo study. BMC Cancer. 2016; 16(1):846. PMC: 5096330. DOI: 10.1186/s12885-016-2865-1. View

Goodheart M, Ritchie J, Rose S, Fruehauf J, De Young B, Buller R . The relationship of molecular markers of p53 function and angiogenesis to prognosis of stage I epithelial ovarian cancer. Clin Cancer Res. 2005; 11(10):3733-42. DOI: 10.1158/1078-0432.CCR-04-0056. View

Gong C, Yang Z, Wu F, Han L, Liu Y, Gong W . miR-17 inhibits ovarian cancer cell peritoneal metastasis by targeting ITGA5 and ITGB1. Oncol Rep. 2016; 36(4):2177-83. DOI: 10.3892/or.2016.4985. View

Lei L, Su J, Chen J, Chen W, Chen X, Peng C . The role of lysophosphatidic acid in the physiology and pathology of the skin. Life Sci. 2018; 220:194-200. DOI: 10.1016/j.lfs.2018.12.040. View

Qin W, Ren Q, Liu T, Huang Y, Wang J . MicroRNA-155 is a novel suppressor of ovarian cancer-initiating cells that targets CLDN1. FEBS Lett. 2013; 587(9):1434-9. DOI: 10.1016/j.febslet.2013.03.023. View

Hurst J, Hooks S . Lysophosphatidic acid stimulates cell growth by different mechanisms in SKOV-3 and Caov-3 ovarian cancer cells: distinct roles for Gi- and Rho-dependent pathways. Pharmacology. 2009; 83(6):333-47. DOI: 10.1159/000217582. View

10.

Fortuna D, Boman B, ONeill R, Palazzo J . MCM2 expression in serrated polyps demonstrates aberrant cellular proliferation. Hum Pathol. 2017; 63:177-183. DOI: 10.1016/j.humpath.2017.02.020. View

11.

Izzotti A, Longobardi M, La Maestra S, Micale R, Pulliero A, Camoirano A . Release of MicroRNAs into Body Fluids from Ten Organs of Mice Exposed to Cigarette Smoke. Theranostics. 2018; 8(8):2147-2160. PMC: 5928877. DOI: 10.7150/thno.22726. View

12.

Webb P, Jordan S . Epidemiology of epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 2016; 41:3-14. DOI: 10.1016/j.bpobgyn.2016.08.006. View

13.

Park J, Jang J, Oh S, Kim M, Shin C, Jeong M . LPA-induced migration of ovarian cancer cells requires activation of ERM proteins via LPA and LPA. Cell Signal. 2018; 44:138-147. DOI: 10.1016/j.cellsig.2018.01.007. View

14.

Armstrong D, Alvarez R, Bakkum-Gamez J, Barroilhet L, Behbakht K, Berchuck A . NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019. J Natl Compr Canc Netw. 2019; 17(8):896-909. DOI: 10.6004/jnccn.2019.0039. View

15.

Sokolowska J, Urbanska K . Immunohistochemical assessment of metalloproteinases MMP2 and MMP9 expression in canine various subtypes of lymphomas in relation with proliferative and apoptotic markers. Pol J Vet Sci. 2019; 22(2):203-211. DOI: 10.24425/pjvs.2019.127087. View

16.

Lin Y, Chen C, Chen W, Lu K, Shen T, Jou Y . LPA signaling mediates tumor lymphangiogenesis through promoting CRT expression in prostate cancer. Biochim Biophys Acta Mol Cell Biol Lipids. 2018; 1863(10):1305-1315. DOI: 10.1016/j.bbalip.2018.07.005. View

17.

Zheng H, Zhang L, Zhao Y, Yang D, Song F, Wen Y . Plasma miRNAs as diagnostic and prognostic biomarkers for ovarian cancer. PLoS One. 2013; 8(11):e77853. PMC: 3815222. DOI: 10.1371/journal.pone.0077853. View

18.

Zeng L, Qian J, Zhu F, Wu F, Zhao H, Zhu H . The prognostic values of matrix metalloproteinases in ovarian cancer. J Int Med Res. 2019; 48(1):300060519825983. PMC: 7140190. DOI: 10.1177/0300060519825983. View

19.

Li C, Duan P, Wang J, Lu X, Cheng J . miR-320 inhibited ovarian cancer oncogenicity via targeting TWIST1 expression. Am J Transl Res. 2017; 9(8):3705-3713. PMC: 5575184. View

20.

Park S, Jeong K, Panupinthu N, Yu S, Lee J, Han J . Lysophosphatidic acid augments human hepatocellular carcinoma cell invasion through LPA1 receptor and MMP-9 expression. Oncogene. 2010; 30(11):1351-9. DOI: 10.1038/onc.2010.517. View